These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 31524529)

  • 1. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
    Bärenwaldt A; Läubli H
    Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
    [No Abstract]   [Full Text] [Related]  

  • 2. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
    van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
    Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.
    Adams OJ; Stanczak MA; von Gunten S; Läubli H
    Glycobiology; 2018 Sep; 28(9):640-647. PubMed ID: 29309569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siglec Signaling in the Tumor Microenvironment.
    van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
    Front Immunol; 2021; 12():790317. PubMed ID: 34966391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting glyco-immune checkpoints for cancer therapy.
    Manni M; Läubli H
    Expert Opin Biol Ther; 2021 Aug; 21(8):1063-1071. PubMed ID: 33502268
    [No Abstract]   [Full Text] [Related]  

  • 6. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.
    Stanczak MA; Siddiqui SS; Trefny MP; Thommen DS; Boligan KF; von Gunten S; Tzankov A; Tietze L; Lardinois D; Heinzelmann-Schwarz V; von Bergwelt-Baildon M; Zhang W; Lenz HJ; Han Y; Amos CI; Syedbasha M; Egli A; Stenner F; Speiser DE; Varki A; Zippelius A; Läubli H
    J Clin Invest; 2018 Nov; 128(11):4912-4923. PubMed ID: 30130255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
    Daly J; Carlsten M; O'Dwyer M
    Front Immunol; 2019; 10():1047. PubMed ID: 31143186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Siglec and anti-Siglec therapies.
    Murugesan G; Weigle B; Crocker PR
    Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities.
    Haas Q; Markov N; Muerner L; Rubino V; Benjak A; Haubitz M; Baerlocher GM; Ng CKY; Münz C; Riether C; Ochsenbein AF; Simon HU; von Gunten S
    Front Immunol; 2022; 13():996746. PubMed ID: 36211376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
    Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
    Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viewing Siglecs through the lens of tumor immunology.
    Fraschilla I; Pillai S
    Immunol Rev; 2017 Mar; 276(1):178-191. PubMed ID: 28258691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tools to study and target the Siglec-sialic acid axis in cancer.
    Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
    FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sialic Acid-Siglec Axis as Molecular Checkpoints Targeting of Immune System: Smart Players in Pathology and Conventional Therapy.
    Wielgat P; Rogowski K; Niemirowicz-Laskowska K; Car H
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human sialoglycan ligands for immune inhibitory Siglecs.
    Gonzalez-Gil A; Li TA; Kim J; Schnaar RL
    Mol Aspects Med; 2023 Apr; 90():101110. PubMed ID: 35965135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The sialoglycan-Siglec-E checkpoint axis in dexamethasone-induced immune subversion in glioma-microglia transwell co-culture system.
    Wielgat P; Czarnomysy R; Trofimiuk E; Car H
    Immunol Res; 2019 Oct; 67(4-5):348-357. PubMed ID: 31741237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
    Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
    Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Siglec receptors as new immune checkpoints in cancer.
    Stanczak MA; Läubli H
    Mol Aspects Med; 2023 Apr; 90():101112. PubMed ID: 35948467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7.
    Fan T; Liao Q; Zhao Y; Dai H; Song S; He T; Wang Z; Huang J; Zeng Z; Guo H; Zhang H; Qiu X
    Cancer Sci; 2023 Feb; 114(2):370-383. PubMed ID: 36310398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
    Boelaars K; van Kooyk Y
    Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy.
    Rodrigues Mantuano N; Natoli M; Zippelius A; Läubli H
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.